Taiwan · Delayed Price · Currency is TWD Steminent Biotherapeutics Statistics
Total Valuation
TPEX:7729 has a market cap or net worth of TWD 6.12 billion. The enterprise value is 5.29 billion.
| Market Cap | 6.12B |
| Enterprise Value | 5.29B |
Important Dates
The next estimated earnings date is Friday, December 18, 2026.
| Earnings Date | Dec 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TPEX:7729 has 80.58 million shares outstanding. The number of shares has increased by 20.73% in one year.
| Current Share Class | 80.58M |
| Shares Outstanding | 80.58M |
| Shares Change (YoY) | +20.73% |
| Shares Change (QoQ) | +19.35% |
| Owned by Insiders (%) | 1.46% |
| Owned by Institutions (%) | 7.68% |
| Float | 62.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 6.06 |
| P/TBV Ratio | 6.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.85, with a Debt / Equity ratio of 0.07.
| Current Ratio | 21.85 |
| Quick Ratio | 20.89 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.39 |
| Interest Coverage | -100.16 |
Financial Efficiency
Return on equity (ROE) is -31.72% and return on invested capital (ROIC) is -18.07%.
| Return on Equity (ROE) | -31.72% |
| Return on Assets (ROA) | -17.62% |
| Return on Invested Capital (ROIC) | -18.07% |
| Return on Capital Employed (ROCE) | -19.68% |
| Weighted Average Cost of Capital (WACC) | 4.95% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | 0.27 |
Taxes
| Income Tax | -111,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +69.06% in the last 52 weeks. The beta is 0.13, so TPEX:7729's price volatility has been lower than the market average.
| Beta (5Y) | 0.13 |
| 52-Week Price Change | +69.06% |
| 50-Day Moving Average | 76.66 |
| 200-Day Moving Average | 71.93 |
| Relative Strength Index (RSI) | 44.85 |
| Average Volume (20 Days) | 350,979 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -3.45M |
| Operating Income | -208.54M |
| Pretax Income | -204.58M |
| Net Income | -204.46M |
| EBITDA | -189.03M |
| EBIT | -208.54M |
| Earnings Per Share (EPS) | -3.03 |
Balance Sheet
The company has 891.65 million in cash and 69.61 million in debt, with a net cash position of 822.03 million or 10.20 per share.
| Cash & Cash Equivalents | 891.65M |
| Total Debt | 69.61M |
| Net Cash | 822.03M |
| Net Cash Per Share | 10.20 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 12.53 |
| Working Capital | 891.22M |
Cash Flow
In the last 12 months, operating cash flow was -173.71 million and capital expenditures -5.12 million, giving a free cash flow of -178.83 million.
| Operating Cash Flow | -173.71M |
| Capital Expenditures | -5.12M |
| Depreciation & Amortization | 19.51M |
| Net Borrowing | -13.98M |
| Free Cash Flow | -178.83M |
| FCF Per Share | -2.22 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TPEX:7729 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.73% |
| Shareholder Yield | -20.73% |
| Earnings Yield | -3.34% |
| FCF Yield | -2.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |